×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu

Tag: ALD

Broker News

ALD – Macquarie rates the stock as Outperform

January 15, 2021 - by Broker News

Backed by lower crude premiums, Ampol’s Lytton refinery saw its December quarter operating loss go down to -$4m, a far cry from the -$82m loss seen in the third quarter. Outperform retained with a target price of $34.65.

Read More
Markets / Shares

Odds Lengthening of Canadians Renewing Their Interest in Ampol

January 14, 2021January 14, 2021 - by Glenn Dyer

The chances have lessened that Alimentation Couche-Tard will renew its interest in Ampol and its fleet of convenience stores with news that the Canadian group is sniffing around French retailer, Carrefour SA.

Read More
Shares

Enthusiasm Wanes After Ampol Rally

November 24, 2020November 24, 2020 - by Eva Brocklehurst

Enthusiasm for Ampol has softened despite a positive update, as the market awaits a decision on the Lytton refinery amid a cloudy outlook for fuel margins

Read More
Shares

Ampol Flags Buyback After Completing Convenience Store Exit

November 24, 2020November 24, 2020 - by Glenn Dyer

Ampol shares jumped to an eight-month high yesterday after the oil group announced a $300 million off-market buyback on the completion of its retail convenience property sale.

Read More
Shares

Refinery Losses Blow Out At Ampol

October 20, 2020October 19, 2020 - by Glenn Dyer

Weak margins from its under review Lytton refinery in Brisbane saw Ampol’s third-quarter earnings slide by around 75%. The weak result from Lytton more than offset an improvement in returns from convenience retailing chain.

Read More
Shares

Ampol Mulls Shutting Down Brisbane Refinery

October 9, 2020October 8, 2020 - by Glenn Dyer

Ampol has put its only oil refinery under review and will consider options including its closure, even after the Morrison government last month unveiled a $2.5 billion rescue package intended to keep refineries open.

Read More
Broker News

ALD – Morgan Stanley rates the stock as Overweight

September 2, 2020 - by Broker News

Chevron has commenced legal proceedings in respect of signage at 177 retail sites across Australia. Ampol’s licence agreement with Chevron was terminated at the end of 2019 with the work-out period up to 2022 and Ampol has started removing the Caltex brand.

Read More
  • Lunch Report: Energy, mining & bank stocks drag market lower
  • RIO – Macquarie rates the stock as Outperform
  • STO – Citi rates the stock as Downgrade to Neutral from Buy
  • PDL – Morgan Stanley rates the stock as Overweight
  • Australia…One Hour In…ASX down 48 points
  • Morning Report: Key US sharemarkets eased on Friday
  • Netflix Heads US Earnings Reports for the Upcoming Week
  • All Eyes on BHP, Rio Production Numbers

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Car.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Key.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Key.